Navigation Links
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Date:5/18/2009

OSAKA, Japan, and IRVINE, Calif., May 18 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and IDM Pharma, Inc. (Nasdaq: IDMI) today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda (Takeda America), and IDM Pharma have entered into an agreement for Takeda America to acquire IDM Pharma. Takeda America has established Jade Subsidiary Corporation as a wholly-owned subsidiary to effect that transaction. Under the agreement, Takeda America will purchase all of IDM Pharma's outstanding shares for US$2.64 per share in an all cash tender offer followed by a merger.

Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology strategy and development, will have global development responsibility for MEPACT(R), IDM Pharma's primary asset, and Takeda Pharmaceuticals Europe Ltd. will be responsible for commercializing MEPACT in Europe.

IDM Pharma received European marketing approval for MEPACT (mifamurtide), a therapy indicated for the treatment of non-metastatic osteosarcoma (malignant bone cancer) following surgical removal of the tumor (resection) in children, adolescents and young adults. Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year. The disease affects primarily children and young adults. The European Commission formally granted a centralized marketing authorization for MEPACT on March 6, 2009, allowing it to be marketed in the 27 EU member states, as well as in Iceland, Liechtenstein and Norway.

"MEPACT delivers a demonstrated survival advantage for young patients with a specific type of bone cancer and provides Takeda with an approved therapy that contributes immediately to our top-line growth," said Erich Brunn, CEO of Taked
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Takeda to Create Global Centers of Excellence
2. Takeda Receives New Information on Alogliptin (SYR-322) NDA
3. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
4. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
5. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
6. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. Takeda Completes Acquisition of Millennium
9. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
10. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
11. Takeda Announces New U.S. Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... one in five patients operated on for broken bones or ... a new study finds. Less-educated patients and patients ... likely to be "doctor shoppers," said study lead author Dr. ... Overall, he said, the study suggests that doctors aren,t talking ...
(Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
(Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... simple sugar is in fact a critical regulator of ... when disturbed, this process could contribute to cancer or ... and timing of cell division, the researchers say. , ... used inside cells to modify proteins, turning the proteins ...
... range of user-controlled products that would help women protect ... be developed in any form that is convenient to ... ,These microbicides will enable women to negotiate ... at risk and would also help avoid unwanted pregnancies, ...
... a rare, benign intra-articular lesion of unknown aetiology. //It ... synovium, and forms part of the differential diagnosis for ... 50 cases of Lipoma arborescens have previously been reported, ... of other joints including the hip, shoulder, wrist and ...
... continues to grow and currently affects more that ... emphasize a need for alternative diabetes therapies with ... ,The delivery of insulin by the lung may ... diabetes. However, alternative insulin delivery systems must meet ...
... successful completion of Phase II clinical trials of a novel ... suppressing the immune system has been announced by Researchers at ... chronic, painful disease affecting millions worldwide. It is thrice more ... age. It strikes joints on both sides of the body, ...
... to hold on to technological advancements belived to revolutionise ... of computers to improve the quality and effectiveness of ... has now been proved with authencity that even pateints ... successfully educated about health topics using computers that can ...
Cached Medicine News:Health News:Sugar Helps Control Cell Division 2Health News:Lipoma Arborescens: A Rare Tumor Of The Knee 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Novel drug holds promise for treatment of Rheumatoid Arthritis 2Health News:Computers Can Teach Patients About Screening for Cancer 2
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... that results from the REMEDEE study ( R andomized ... inal sirolimus coat ED bio- E ... Therapy Stent is non-inferior to the TAXUS® Liberte® paclitaxel-eluting stent, with ... results were presented by Michael Haude, M.D., director of Medical Clinic ...
... University Hospitals (UH) Case Medical Center, Case Western ... today the initiation of a novel Phase I clinical ... hematopoietic stem cells (HSCs) from the dose limiting toxicity ... Americans are diagnosed with glioblastoma every year and only ...
Cached Medicine Technology:REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 2REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 3REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 4Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
Medicine Products: